2024 Q3 Form 10-Q Financial Statement

#000143774924025880 Filed on August 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $829.0K $1.462M
YoY Change -28.53% 63.17%
% of Gross Profit
Research & Development $2.327M $1.361M
YoY Change 156.56% -55.04%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.327M $1.361M
YoY Change 156.56% -55.04%
Operating Profit -$3.156M -$2.823M
YoY Change 52.61% -28.04%
Interest Expense $51.00K $52.00K
YoY Change 410.0% -8.77%
% of Operating Profit
Other Income/Expense, Net $69.00K $122.0K
YoY Change -97.33% -231.18%
Pretax Income -$3.087M -$2.701M
YoY Change -705.29% -32.74%
Income Tax
% Of Pretax Income
Net Earnings -$3.076M -$2.692M
YoY Change -699.61% -32.97%
Net Earnings / Revenue
Basic Earnings Per Share -$1.92 -$6.43
Diluted Earnings Per Share -$1.92 -$2.41
COMMON SHARES
Basic Shares Outstanding 1.431M 941.0K
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.597M $4.919M
YoY Change 1523.13% 213.11%
Cash & Equivalents $2.597M $4.919M
Short-Term Investments
Other Short-Term Assets $28.00K $69.00K
YoY Change -91.52% 0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $2.625M $4.988M
YoY Change 425.0% 199.4%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $2.625M $4.988M
Total Long-Term Assets $0.00 $0.00
Total Assets $2.625M $4.988M
YoY Change 422.91% 199.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $657.0K $592.0K
YoY Change 121.96% 32.74%
Accrued Expenses $287.0K $522.0K
YoY Change -79.93% -65.06%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $973.0K $1.161M
YoY Change -80.63% -85.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $973.0K $1.161M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $973.0K $1.161M
YoY Change -80.63% -85.14%
SHAREHOLDERS EQUITY
Retained Earnings -$101.0M -$98.00M
YoY Change 10.26% 6.41%
Common Stock $0.00 $0.00
YoY Change -100.0% -100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.610M $4.764M
YoY Change
Total Liabilities & Shareholders Equity $2.625M $4.988M
YoY Change 422.91% 199.4%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$3.076M -$2.692M
YoY Change -699.61% -32.97%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.889M -$2.253M
YoY Change 224.61% -51.7%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 567.0K 3.978M
YoY Change 18.13%
NET CHANGE
Cash From Operating Activities -2.889M -2.253M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 567.0K 3.978M
Net Change In Cash -2.322M 1.725M
YoY Change 64.68% -125.88%
FREE CASH FLOW
Cash From Operating Activities -$2.889M -$2.253M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity File Number
EntityFileNumber
001-38114
dei Local Phone Number
LocalPhoneNumber
652‑4500
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
250000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
250000
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
250000
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
250000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1189724
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1189724
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
341324
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
341324
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
75 pure
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4113275
dei Entity Address Address Line1
EntityAddressAddressLine1
1111 Kane Concourse, Suite 301
dei Entity Address City Or Town
EntityAddressCityOrTown
Bay Harbor Islands
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33154
dei City Area Code
CityAreaCode
781
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
ATXI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1431356
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4919000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1783000 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
69000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
67000 usd
CY2024Q2 us-gaap Assets
Assets
4988000 usd
CY2023Q4 us-gaap Assets
Assets
1850000 usd
CY2024Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
47000 usd
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
586000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1161000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1196000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
1161000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
1196000 usd
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
102724000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
92507000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-97960000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-90928000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
4764000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1582000 usd
CY2024Q2 us-gaap Minority Interest
MinorityInterest
-937000 usd
CY2023Q4 us-gaap Minority Interest
MinorityInterest
-928000 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3827000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
654000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4988000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1850000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1361000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3027000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3752000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4242000 usd
CY2024Q2 atxi Research And Development Expense For Licenses Acquired
ResearchAndDevelopmentExpenseForLicensesAcquired
0 usd
CY2023Q2 atxi Research And Development Expense For Licenses Acquired
ResearchAndDevelopmentExpenseForLicensesAcquired
0 usd
atxi Research And Development Expense For Licenses Acquired
ResearchAndDevelopmentExpenseForLicensesAcquired
0 usd
atxi Research And Development Expense For Licenses Acquired
ResearchAndDevelopmentExpenseForLicensesAcquired
4230000 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1462000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
896000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2778000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1880000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2823000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3923000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6530000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-10352000 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
52000 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
57000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
100000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
94000 usd
CY2024Q2 atxi Financing Costs Warrant Liabilities
FinancingCostsWarrantLiabilities
-0 usd
CY2023Q2 atxi Financing Costs Warrant Liabilities
FinancingCostsWarrantLiabilities
-0 usd
atxi Financing Costs Warrant Liabilities
FinancingCostsWarrantLiabilities
-0 usd
atxi Financing Costs Warrant Liabilities
FinancingCostsWarrantLiabilities
332000 usd
CY2024Q2 atxi Loss On Warrant Liabilities Classified As Inducement Fee
LossOnWarrantLiabilitiesClassifiedAsInducementFee
185000 usd
CY2023Q2 atxi Loss On Warrant Liabilities Classified As Inducement Fee
LossOnWarrantLiabilitiesClassifiedAsInducementFee
-0 usd
atxi Loss On Warrant Liabilities Classified As Inducement Fee
LossOnWarrantLiabilitiesClassifiedAsInducementFee
759000 usd
atxi Loss On Warrant Liabilities Classified As Inducement Fee
LossOnWarrantLiabilitiesClassifiedAsInducementFee
-0 usd
CY2024Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-255000 usd
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
150000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-139000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1028000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
122000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-93000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-520000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1266000 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-2701000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-4016000 usd
us-gaap Profit Loss
ProfitLoss
-7050000 usd
us-gaap Profit Loss
ProfitLoss
-11618000 usd
CY2024Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-9000 usd
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-9000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-18000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-75000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2692000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4007000 usd
us-gaap Net Income Loss
NetIncomeLoss
-7032000 usd
us-gaap Net Income Loss
NetIncomeLoss
-11543000 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7186000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4007000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15842000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11543000 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.43
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-38.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-18.86
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-129.84
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1117769
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
103442
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
839900
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88901
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1898000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
192000 usd
CY2024Q2 atxi Common Shares Issuable Founders Agreement
CommonSharesIssuableFoundersAgreement
-8000 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
172000 usd
CY2024Q2 atxi Adjustments To Apic Loss On Settlement Of Common Stock Warrant Liabilities
AdjustmentsToApicLossOnSettlementOfCommonStockWarrantLiabilities
296000 usd
CY2024Q2 atxi Stock Issued During Period Value Exercise0f Warrants
StockIssuedDuringPeriodValueExercise0fWarrants
4448000 usd
CY2024Q2 atxi Adjustments To Additional Paid In Capital Warrant Inducement Offering Costs
AdjustmentsToAdditionalPaidInCapitalWarrantInducementOfferingCosts
765000 usd
CY2024Q2 atxi Stock Issued During Period Value Reverse Stock Splits
StockIssuedDuringPeriodValueReverseStockSplits
0 usd
CY2024Q2 atxi Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance
AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance
0 usd
CY2024Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-9000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2692000 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3827000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
654000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
383000 usd
atxi Common Shares Issuable Founders Agreement
CommonSharesIssuableFoundersAgreement
-371000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
543000 usd
atxi Adjustments To Apic Loss On Settlement Of Common Stock Warrant Liabilities
AdjustmentsToApicLossOnSettlementOfCommonStockWarrantLiabilities
1159000 usd
atxi Stock Issued During Period Value Exercise0f Warrants
StockIssuedDuringPeriodValueExercise0fWarrants
9421000 usd
atxi Adjustments To Additional Paid In Capital Warrant Inducement Offering Costs
AdjustmentsToAdditionalPaidInCapitalWarrantInducementOfferingCosts
-1207000 usd
atxi Stock Issued During Period Value Reverse Stock Splits
StockIssuedDuringPeriodValueReverseStockSplits
0 usd
atxi Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance
AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance
0 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-18000 usd
us-gaap Net Income Loss
NetIncomeLoss
-7032000 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3827000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2157000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
27000 usd
CY2023Q2 atxi Stock Issued During Period Value Exercise0f Warrants
StockIssuedDuringPeriodValueExercise0fWarrants
0 usd
CY2023Q2 atxi Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance
AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance
0 usd
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-9000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4007000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-6146000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3266000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
38000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
72000 usd
atxi Shares And Warrants Issued During Period Value
SharesAndWarrantsIssuedDuringPeriodValue
866000 usd
atxi Stock Issued During Period Value License Expense
StockIssuedDuringPeriodValueLicenseExpense
1230000 usd
atxi Stock Issued During Period Value Exercise0f Warrants
StockIssuedDuringPeriodValueExercise0fWarrants
0 usd
atxi Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance
AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance
0 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-75000 usd
us-gaap Net Income Loss
NetIncomeLoss
-11543000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-6146000 usd
us-gaap Profit Loss
ProfitLoss
-7050000 usd
us-gaap Profit Loss
ProfitLoss
-11618000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
383000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
38000 usd
atxi Loss On Warrant Liabilities Classified As Inducement Fee
LossOnWarrantLiabilitiesClassifiedAsInducementFee
759000 usd
atxi Loss On Warrant Liabilities Classified As Inducement Fee
LossOnWarrantLiabilitiesClassifiedAsInducementFee
0 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-139000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1028000 usd
atxi Issuance Of Stock For Licenses Acquired
IssuanceOfStockForLicensesAcquired
0 usd
atxi Issuance Of Stock For Licenses Acquired
IssuanceOfStockForLicensesAcquired
1230000 usd
atxi Research And Development License Acquried Expense
ResearchAndDevelopmentLicenseAcquriedExpense
0 usd
atxi Research And Development License Acquried Expense
ResearchAndDevelopmentLicenseAcquriedExpense
2000000 usd
atxi Common Stock Issued To Fortress Value
CommonStockIssuedToFortressValue
543000 usd
atxi Common Stock Issued To Fortress Value
CommonStockIssuedToFortressValue
72000 usd
atxi Issuance Of Stock Under Founders Agreement
IssuanceOfStockUnderFoundersAgreement
-371000 usd
atxi Issuance Of Stock Under Founders Agreement
IssuanceOfStockUnderFoundersAgreement
0 usd
us-gaap Increase Decrease In Due From Other Related Parties Current
IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent
-0 usd
us-gaap Increase Decrease In Due From Other Related Parties Current
IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent
26000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-68000 usd
atxi Increase Decrease In Accrued Licenses Acquired
IncreaseDecreaseInAccruedLicensesAcquired
0 usd
atxi Increase Decrease In Accrued Licenses Acquired
IncreaseDecreaseInAccruedLicensesAcquired
1000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5373000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6238000 usd
atxi Payments To Acquire Research And Development Licenses
PaymentsToAcquireResearchAndDevelopmentLicenses
-0 usd
atxi Payments To Acquire Research And Development Licenses
PaymentsToAcquireResearchAndDevelopmentLicenses
2000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2000000 usd
atxi Issuance Of Common Stock Prefund Warrants And Warrants
IssuanceOfCommonStockPrefundWarrantsAndWarrants
0 usd
atxi Issuance Of Common Stock Prefund Warrants And Warrants
IssuanceOfCommonStockPrefundWarrantsAndWarrants
3101000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
295000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
9421000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
atxi Payments Of Warrants Exercise Transaction Costs
PaymentsOfWarrantsExerciseTransactionCosts
1207000 usd
atxi Payments Of Warrants Exercise Transaction Costs
PaymentsOfWarrantsExerciseTransactionCosts
-0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8509000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3101000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
3136000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-5137000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1783000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6708000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4919000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1571000 usd
atxi Unpaid Research And Development Licenses Acquired
UnpaidResearchAndDevelopmentLicensesAcquired
0 usd
atxi Unpaid Research And Development Licenses Acquired
UnpaidResearchAndDevelopmentLicensesAcquired
1000000 usd
us-gaap Stock Issued1
StockIssued1
543000 usd
us-gaap Stock Issued1
StockIssued1
0 usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-98000000 usd
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 pure
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2024Q2 atxi Deemed Dividends
DeemedDividends
4500000 usd
atxi Deemed Dividends
DeemedDividends
8800000 usd
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1499925
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
105051
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
286912
CY2019Q4 atxi Contractual Obligation Development Expense
ContractualObligationDevelopmentExpense
81500000 usd
CY2019Q4 atxi Contractual Obligation Commercial Expense
ContractualObligationCommercialExpense
151000000 usd
CY2016Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1311000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
196.21
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
-0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
283000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
85.5
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1028000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
226.69
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1028000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
226.69
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
22474000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
85.5
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y6M
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
-0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
-0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
-0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
22474000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
85.5
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
16304000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
85.5
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6170000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
85.5
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
192000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
27000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
383000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
38000 usd
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
524601
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
32.42
CY2023 atxi Class Of Warrant Or Right Aggregate Intrinsic Value
ClassOfWarrantOrRightAggregateIntrinsicValue
0 usd
CY2024Q1 atxi Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
441076
CY2024Q1 atxi Class Of Warrant Or Right Granted During Period Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightGrantedDuringPeriodExercisePriceOfWarrantsOrRights
6.2
CY2024Q1 atxi Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
220538
CY2024Q1 atxi Class Of Warrant Or Right Exercised During Period Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisedDuringPeriodExercisePriceOfWarrantsOrRights
22.55
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
745139
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
29.5
CY2024Q1 atxi Class Of Warrant Or Right Aggregate Intrinsic Value
ClassOfWarrantOrRightAggregateIntrinsicValue
0 usd
CY2024Q2 atxi Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
1420741
CY2024Q2 atxi Class Of Warrant Or Right Granted During Period Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightGrantedDuringPeriodExercisePriceOfWarrantsOrRights
6.25
CY2024Q2 atxi Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
689680
CY2024Q2 atxi Class Of Warrant Or Right Exercised During Period Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisedDuringPeriodExercisePriceOfWarrantsOrRights
6.2
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1476200
CY2024Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
8.64
CY2024Q2 atxi Class Of Warrant Or Right Aggregate Intrinsic Value
ClassOfWarrantOrRightAggregateIntrinsicValue
0 usd

Files In Submission

Name View Source Status
0001437749-24-025880-index-headers.html Edgar Link pending
0001437749-24-025880-index.html Edgar Link pending
0001437749-24-025880.txt Edgar Link pending
0001437749-24-025880-xbrl.zip Edgar Link pending
atxi-20240630.xsd Edgar Link pending
atxi20240630_10q.htm Edgar Link pending
ex_677266.htm Edgar Link pending
ex_677267.htm Edgar Link pending
ex_677268.htm Edgar Link pending
ex_677269.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
atxi-20240630_def.xml Edgar Link unprocessable
atxi-20240630_lab.xml Edgar Link unprocessable
atxi-20240630_pre.xml Edgar Link unprocessable
atxi20240630_10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
atxi-20240630_cal.xml Edgar Link unprocessable